The US Food and Drug Administration’s latest expansion of the COVID-19 vaccine emergency use authorization is the largest yet without consulting its advisory committee, but fits a recent pattern with incremental decisions.
The agency announced 29 March that it had authorized a second booster of the Pfizer Inc./BioNTech SE or...







